GlassScriptPhysician profile
Jessica Ruth Meyer
NPI 1629500970
$4,587.56
in general payments reported to CMS, 2019-2025
24 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.86 · 2023: $476 · 2024: $2,021 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,505 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.71 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.50 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $854.07 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $826.88 | 2023-2025 | |
| Astellas Pharma US INC | $287.41 | 2024-2025 | Veozah |
| Lilly USA, LLC | $240.20 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $240.12 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $231.78 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $164.42 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $132.24 | 2023-2025 | |
| Lundbeck LLC | $83.02 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $79.16 | 2023-2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.59 | 2025 | Caplyta |
| Actelion Pharmaceuticals US, INC. | $66.54 | 2023-2025 | Opsumit, Uptravi |
| Verona Pharma, INC. | $61.98 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $60.43 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $57.79 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $51.82 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $33.87 | 2025 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $30.07 | 2024 | |
| Gilead Sciences, INC. | $28.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.59 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.31 | 2024 | Trulance, Xifaxan |
| Alkermes, INC. | $17.04 | 2024 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $15.45 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.